Pages that link to "Q73568053"
Jump to navigation
Jump to search
The following pages link to Olivier Rixe (Q73568053):
Displaying 50 items.
- Cyclooxygenase-2 as a target for anticancer drug development (Q28195645) (← links)
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study (Q28282189) (← links)
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma (Q28282757) (← links)
- A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study (Q33410742) (← links)
- Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies (Q33423203) (← links)
- A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies (Q33735754) (← links)
- The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma (Q33929529) (← links)
- Metastatic melanoma: chemotherapy (Q34156931) (← links)
- Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis (Q34245458) (← links)
- Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors (Q34334516) (← links)
- Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study (Q34584163) (← links)
- Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation (Q35221471) (← links)
- Lung cancer in patients with HIV Infection and review of the literature (Q35858070) (← links)
- High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses (Q36117735) (← links)
- Proteasome inhibition: a new approach for the treatment of malignancies. (Q36326490) (← links)
- Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension (Q36894975) (← links)
- Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? (Q37038239) (← links)
- Validation of analytic methods for biomarkers used in drug development (Q37284255) (← links)
- Renal toxicity of targeted therapies (Q37473177) (← links)
- Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor (Q37624473) (← links)
- Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study (Q37639225) (← links)
- Axitinib (AG-013736). (Q37674170) (← links)
- Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity (Q37816164) (← links)
- Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma (Q38514440) (← links)
- Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice (Q39398750) (← links)
- Sunitinib malate (Q40202597) (← links)
- Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study (Q40510197) (← links)
- A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer (Q41129245) (← links)
- Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib (Q41496075) (← links)
- Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design (Q42627893) (← links)
- Renal cell carcinoma: ten years of significant advances (Q42939988) (← links)
- Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report (Q42995703) (← links)
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). (Q43181709) (← links)
- Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! (Q43918759) (← links)
- Biochemotherapy for advanced melanoma: maybe it is real (Q43993862) (← links)
- Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction (Q44200284) (← links)
- Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study (Q44683203) (← links)
- Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model (Q44943010) (← links)
- Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma (Q45011636) (← links)
- Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report) (Q45069493) (← links)
- Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). (Q45073982) (← links)
- Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck (Q45256975) (← links)
- Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study (Q45271732) (← links)
- Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours (Q45378137) (← links)
- Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma (Q46202007) (← links)
- Scrotal cutaneous side effects of sunitinib (Q46406836) (← links)
- Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study (Q46511013) (← links)
- Macrocytosis due to treatment with sunitinib (Q46980054) (← links)
- Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients (Q47956458) (← links)
- Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy (Q48102843) (← links)